About Us
Myrexis, Inc. is a biotechnology company discovering, developing and commercializing novel therapies for the treatment of cancer. Our pipeline includes clinical and pre-clinical product candidates with distinct mechanisms of action and novel chemical structures that have the potential to be first-in-class and/or best-in-class therapeutics.
The discovery and development of each of our drug candidates has been guided by a unique understanding of the genetic causes of human diseases and the genetic factors that may cause drug side effects, drug interactions, and drug metabolism. Our extensive experience in human genetics, protein-protein interaction technology and chemical proteomic drug discovery has allowed identification of novel drug targets and accelerated progression from chemical lead compounds to investigational drug candidates.
Our corporate strategy:
- Focus resources on lead clinical drug programs
- Expand preclinical pipeline of drug candidates
- Direct discovery programs to address significant unmet needs in oncology
- Partner to maximize the value of our portfolio
To learn more about Myrexis, contact us.
